Moleculin Presents Preliminary Efficacy Findings From Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles Of Annamycin For The Treatment Of Soft Tissue Sarcomas Lung Metastases
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech, Inc. (NASDAQ:MBRX) has presented preliminary efficacy findings from its Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma lung metastases. The trial demonstrated a 64% stable disease rate through two cycles of Annamycin. The drug continues to be 100% non-cardiotoxic and has Fast Track Status and Orphan Drug Designation from the FDA. The company's CEO, Walter Klemp, expressed confidence in the potential of Annamycin to be a meaningful treatment option for patients.
November 06, 2023 | 1:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moleculin Biotech's preliminary findings from its Phase 1B/2 clinical trial of Annamycin show promising results, potentially boosting investor confidence in the company's pipeline.
The positive preliminary results from the Phase 1B/2 clinical trial of Annamycin, a drug developed by Moleculin Biotech, could potentially boost investor confidence in the company's pipeline. The drug has shown a 64% stable disease rate in treating soft tissue sarcoma lung metastases and has received Fast Track Status and Orphan Drug Designation from the FDA, indicating its potential for approval and market success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100